World News Insights
1-3 Minute Gist
Search, personalize, or simply browse. Follow the world around you from gist and context to insights.
Who we are | Our Credo | Ways of using Lyrarc | FAQ | Send Feedback | First Letter From the Editor
Sign up. It's free and easy to use
Create an account
to personalize your feed of articles and topics.
All Topics Article
Abbott to Split Into Two Companies
Keywords:
Abbott Labs will split into two publicly traded companies, with a medical products company including products such as Similac, Ensure and stent devices, and a pharmaceutical company that would have its Humira rheumatoid arthritis therapy Humira. Humira generates about $8 billion in sales, but faces patent expiration in 2016 and competition from a new drrug expected from Pfizer, as well as generics. Abbott's CEO sees the opportunities in the two products falling in different areas. The medical products business has greater potential in emerging markets, and will require a different focus from the slower growing pharmaceutical business facing competition and payor cost pressures. The medical product company includes a drug coated stent Xience, with $1.5 billion in sales, which has improved prospects as J&J is leaving the stent business. The medical products business sales are 40% from emerging markets, and 40% of revenue comes from patients not from cost conscious governments or insurers, according to CEO White. Its the emerging markets emphasis that convinced White to go with the split. Richard Gonzalez who runs the pharmaceutical business will head the pharmaceutical company, and CEO Miles White will run the medical products company.
Abbott Laboratories.
06/18/2007
Grouped Articles
Abbott Breaks With Industry, Sues AIDS Group
Wall Street Journal 06/18/2007
Glaxo Sues Abbott Labs Over AIDS Drug Pricing
Wall Street Journal 11/09/2007
Abbott to Pay $184 Million In Tricor Suits
Wall Street Journal 11/21/2008
The Unmasking Of Company X Abbott Labs Approached
Wall Street Journal 03/31/2009
Abbott Joins Bidding for Solvay Drug Unit
Wall Street Journal 09/25/2009
Abbott in $6.6 Billion Deal for Drug Unit
New York Times 09/28/2009
Abbott Labs strategies
10/19/2006
Grouped Articles
Abbott Labs Spices Up Its Drug Portfolio
Wall Street Journal 05/22/2010
Abbott Labs to Buy Indian Drug Maker
Wall Street Journal 05/22/2010
Abbott to Split Into Two Companies
Wall Street Journal 10/20/2011
Abbott Labs Licenses Molecules from Reata
Wall Street Journal 12/12/2011
Indiaâs Supreme Court to Hear Dispute on Drug Patents
New York Times 03/06/2012
Abbott Looks to Consumer for Growth
Wall Street Journal 05/03/2012
Abbott Labs management
05/22/2010
Grouped Articles
Abbott Labs to Buy Indian Drug Maker
Wall Street Journal 05/22/2010
Abbott to Split Into Two Companies
Wall Street Journal 10/20/2011
Abbott Looks to Consumer for Growth
Wall Street Journal 05/03/2012
Abbott to Pay $1.6 Billion Over Illegal Marketing
New York Times 05/07/2012
Wall Street Journal 05/08/2012
Abbott restructuring.
08/22/2008
Grouped Articles
Abbott Will Cut 1,000 Jobs in Efficiency Bid
Wall Street Journal 08/22/2008
Abbott Labs to Split into 2 Companies
New York Times 10/20/2011
Abbott to Split Into Two Companies
Wall Street Journal 10/20/2011
Abbott Looks to Consumer for Growth
Wall Street Journal 05/03/2012
Abbott Laboratories to pay $1.6 billion over illegal marketing of Depakote - The Washington Post
Washington Post 05/08/2012
Abbott to Pay $1.6 Billion Over Illegal Marketing
New York Times 05/07/2012
Abbott Labs performance
10/19/2006
Grouped Articles
Abbott Labs Spices Up Its Drug Portfolio
Wall Street Journal 05/22/2010
Abbott Labs to Buy Indian Drug Maker
Wall Street Journal 05/22/2010
Abbott to Split Into Two Companies
Wall Street Journal 10/20/2011
Abbott Labs Licenses Molecules from Reata
Wall Street Journal 12/12/2011
Abbott Looks to Consumer for Growth
Wall Street Journal 05/03/2012
Abbott Is Buoyed By Arthritis Drug, Guidant's Stents - WSJ.com
Wall Street Journal 10/19/2006
Abbott Lab's medical products company and its focus on emerging markets in China and India
10/20/2011
Abbott see the huge potential for infant nutrition and other businesses related to medical products as millons of people join the middle class in China, India, Vietnam and other emerging markets. Nestle is pursuing a similar idea with its acquisition of Pfizer's infant nutrition business which has a large presence in China. With its strong brand name presence, marketing and distribution, and the growing need for better nutrition in these countries Nestle sees huge potential for growth.
Linked Articles
Abbott to Split Into Two Companies
Wall Street Journal 10/20/2011
Abbott Looks to Consumer for Growth
Wall Street Journal 05/03/2012
We took a different way to help millions around the world build educated informed mindsets that affects and shapes their lives. For a future that is open, global and digital, with everyone having access to high quality information. We believe in the renewal of America, renewal of Europe, the renewal of India, the rest of Asia, Latin America and Africa. The renewal of our supply chains, health, education, infrastructure, as we rebuild our countries after the pandemic. Literacy and knowledge we believe cannot thrive and grow in a world of web bots, web crawlers, or AI. This requires human curiosity, human learning, and human imagination. We take as inspiration the saying- “One has to be free, and as broad as sky. One has to have a mind that is crystal clear, only then can truth shine in it.” Every contribution whether big or small is precious- in this crisis and ahead.
Support Lyrarc from as small as $1
Terms and Conditions | Copyright Policy | Privacy Policy | Contact Us